Zobrazeno 1 - 10
of 144
pro vyhledávání: '"Dowlati A"'
Autor:
Jessica Surdam, Afshin Dowlati, Augustine Hong, Pingfu Fu, Neal J. Meropol, Michelle Treasure, Barbara J. Daly, Shufen Cao, Elizabeth Weinstein
Publikováno v:
Cancer Medicine, Vol 10, Iss 13, Pp 4312-4321 (2021)
Cancer Medicine
Cancer Medicine
Purpose Patients enrolled in Phase 1 clinical trials have typically exhausted standard therapies and often are choosing between a clinical trial and hospice care. Significant symptom burden can result in early trial discontinuation and confound trial
Autor:
Saad Sheikh, Sujay Datta, Tithi Biswas, Charulata Jindal, Mitchell Machtay, Tarun Podder, Afshin Dowlati, Asoke Dey, Jimmy T. Efird
Publikováno v:
Future Oncology. 17:2713-2724
The role of prophylactic cranial irradiation (PCI) and thoracic radiation therapy (TRT) in extensive-stage small cell lung cancer remains controversial. The authors examined the National Cancer Database and identified patients with extensive-stage sm
Autor:
Daniel J. Lenihan, Avirup Guha, Jahir M. Gutierrez, Sadeer G. Al-Kindi, Guilherme H. Oliveira, Chhavi Jain, Marcos de Lima, Afshin Dowlati, Michael G. Fradley, Jill S. Barnholtz-Sloan, Prantesh Jain
Publikováno v:
Cancer Medicine, Vol 10, Iss 12, Pp 3862-3872 (2021)
Cancer Medicine
Cancer Medicine
Background Cardiovascular adverse events (CVAEs) associated with BRAF inhibitors alone versus combination BRAF/MEK inhibitors are not fully understood. Methods This study included all adult patients who received BRAF inhibitors (vemurafenib, dabrafen
Autor:
William Jeffery Edenfield, Daniel Da Costa, David Hoffman, Matthew P. Kosloski, Minal A. Barve, Scott A. Laurie, Alexander Starodub, Jonathan W. Goldman, Satwant Lally, Martina M. Koch, Afshin Dowlati, Antoinette J. Wozniak, Jyoti D. Patel, Grace K. Dy, Taofeek K. Owonikoko
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 2, Pp 664-670 (2021)
Clinical and Translational Science
Clinical and Translational Science
Small cell lung cancer (SCLC) is a leading cause of cancer death worldwide, with few treatment options. Rovalpituzumab tesirine (Rova-T) is an antibody-drug conjugate that targets delta-like 3 on SCLC cells to deliver a cytotoxic payload directly to
Autor:
Jonathan W Goldman, Mikhail Dvorkin, Yuanbin Chen, Niels Reinmuth, Katsuyuki Hotta, Dmytro Trukhin, Galina Statsenko, Maximilian J Hochmair, Mustafa Özgüroğlu, Jun Ho Ji, Marina Chiara Garassino, Oleksandr Voitko, Artem Poltoratskiy, Santiago Ponce, Francesco Verderame, Libor Havel, Igor Bondarenko, Andrzej Każarnowicz, György Losonczy, Nikolay V Conev, Jon Armstrong, Natalie Byrne, Piruntha Thiyagarajah, Haiyi Jiang, Luis Paz-Ares, Nataliia Voitko, Andrzej Kazarnowicz, Mustafa Özgüroglu, Nikolay Conev, Maximilian Hochmair, Otto Burghuber, Irfan Çiçin, Vladimir Moiseenko, Mustafa Erman, Dariusz Kowalski, Marek Wojtukiewicz, Hryhoriy Adamchuk, Alexander Vasilyev, Serhii Shevnia, Spartak Valev, Maria Amelia Insa Molla, Grygorii Ursol, Anne Chiang, Sylvia Hartl, Zsolt Horváth, Gábor Pajkos, Sang-We Kim, Alexey Smolin, Tuncay Göksel, Shaker Dakhil, Jaromir Roubec, Krisztina Bogos, Robin Cornelissen, Jong-Seok Lee, Maria Rosario Garcia Campelo, Marta Lopez Brea, Ahmet Alacacioglu, Ignacio Casarini, Rumyana Ilieva, Ivan Tonev, Attila Somfay, Jair Bar, Alona Zer Kuch, Mauro Minelli, Roberta Bartolucci, Fausto Roila, Haruhiro Saito, Koichi Azuma, Gyeong-Won Lee, Alexander Luft, Michal Urda, Juan Ignacio Delgado Mingorance, Margarita Majem Tarruella, David Spigel, Krassimir Koynov, Milada Zemanova, Jens Panse, Christian Schulz, Zsolt Pápai Székely, Veronika Sárosi, Angelo Delmonte, Anna Cecilia Bettini, Makoto Nishio, Isamu Okamoto, Lizza Hendriks, Slawomir Mandziuk, Yun Gyoo Lee, Lyubov Vladimirova, Dolores Isla Casado, Manuel Domine Gomez, Alejandro Navarro Mendivil, Teresa Morán Bueno, Shang-Yin Wu, Jeanna Knoble, Jana Skrickova, Violetka Venkova, Werner Hilgers, Eckart Laack, Helge Bischoff, Andrea Fülöp, Ibolya Laczó, Judit Kósa, András Telekes, Tatsuya Yoshida, Shintaro Kanda, Toyoaki Hida, Hidetoshi Hayashi, Tadashi Maeda, Tetsuji Kawamura, Yasuharu Nakahara, Niels Claessens, Ki Hyeong Lee, Chao-Hua Chiu, Sheng-Hao Lin, Chien-Te Li, Ahmet Demirkazik, Eric Schaefer, Petros Nikolinakos, Jeffrey Schneider, Sunil Babu, Bernd Lamprecht, Michael Studnicka, Carlos Fausto Nino Gorini, Juraj Kultan, Vitezslav Kolek, Pierre-Jean Souquet, Denis Moro-Sibilot, Maya Gottfried, Egbert Smit, Kyung Hee Lee, Peter Kasan, Jozef Chovanec, Olexandr Goloborodko, Oleksii Kolesnik, Yuriy Ostapenko, Shailendra Lakhanpal, Basir Haque, Winston Chua, Joseph Stilwill, Susana Noemi Sena, Gustavo Colagiovanni Girotto, Pedro Rafael Martins De Marchi, Fabricio Augusto Martinelli de Oliveira, Pedro Dos Reis, Rositsa Krasteva, Yanqiu Zhao, Chengshui Chen, Leona Koubkova, Gilles Robinet, Christos Chouaid, Christian Grohe, Jürgen Alt, Eszter Csánky, Éva Somogyiné Ezer, Norman Isaac Heching, Young Hak Kim, Shinji Aatagi, Shoichi Kuyama, Daijiro Harada, Naoyuki Nogami, Hiroshi Nokihara, Hisatsugu Goto, Agnes Staal van den Brekel, Eun Kyung Cho, Joo-Hang Kim, Doina Ganea, Tudor Ciuleanu, Ekaterina Popova, Dina Sakaeva, Marian Stresko, Pavol Demo, Robert Godal, Yu-Feng Wei, Yen-Hsun Chen, Te-Chun Hsia, Kang-Yun Lee, Huang-Chih Chang, Chin-Chou Wang, Afshin Dowlati, Christopher Sumey, Steven Powell, Jonathan Goldman, Juan Jose Zarba, Emilio Batagelj, Andrea Viviana Pastor, Mauro Zukin, Clarissa Serodio da Rocha Baldotto, Luis Alberto Schlittler, Aknar Calabrich, Claudia Sette, Asen Dudov, Caicun Zhou, Hervé Lena, Susanne Lang, Zsuzsanna Pápai, Koichi Goto, Shigeki Umemura, Kenya Kanazawa, Yu Hara, Masahiro Shinoda, Masahiro Morise, Jeroen Hiltermann, Robert Mróz, Andrei Ungureanu, Igor Andrasina, Gee-Chen Chang, Ihor Vynnychenko, Yaroslav Shparyk, Anna Kryzhanivska, Helen Ross, Kailhong Mi, Rodney Jamil, Michael Williamson, Joseph Spahr, Zhigang Han, Mengzhao Wang, Zhixiong Yang, Jie Hu, Wei Li, Jun Zhao, Jifeng Feng, Shenglin Ma, Xiangdong Zhou, Zongan Liang, Yi Hu, Yuan Chen, Minghong Bi, Yongqian Shu, Kejun Nan, Jianying Zhou, Wei Zhang, Rui Ma, Nong Yang, Zhong Lin, Gang Wu, Jian Fang, Helong Zhang, Kai Wang, Zhendong Chen
Publikováno v:
The Lancet Oncology, 22(1), 51-65. Lancet Publishing Group
Background: First-line durvalumab plus etoposide with either cisplatin or carboplatin (platinum–etoposide) showed a significant improvement in overall survival versus platinum–etoposide alone in patients with extensive-stage small-cell lung cance
Autor:
Caron A. Jacobson, Paolo Caimi, Frederic Boisserie, Geoffrey I. Shapiro, Christopher A. French, William E. Pierceall, Jianguo Zhi, Khanh T. Do, Patricia LoRusso, Sharon Passe, Philippe Armand, Emily Labriola-Tompkins, Martin Kornacker, Afshin Dowlati, Mark DeMario, Joseph Paul Eder, Amy Weise, Ulka N. Vaishampayan
Publikováno v:
British Journal of Cancer
Background Bromodomain and extra-terminal (BET) proteins are epigenetic readers that can drive carcinogenesis and therapy resistance. RO6870810 is a novel, small-molecule BET inhibitor. Methods We conducted a Phase 1 study of RO6870810 administered s
Autor:
Victor Moreno, Afshin Dowlati, Xiaomin He, Emiliano Calvo, Debbie Robbrecht, Nital Soni, Juanita Lopez, Natalie Cook, Hirai Hiroshi, Ferry A.L.M. Eskens, Angelica Fasolo, Johann S. de Bono
Publikováno v:
British Journal of Cancer, 124(2), 391-398. Nature Publishing Group
British Journal of Cancer
British Journal of Cancer
BackgroundThis is a first-in-human study with TAS-119, an Aurora A kinase (AurA) inhibitor.MethodsPatients with advanced, refractory, solid tumours were enrolled into 5 dose escalation cohorts (70–300 mg BID, 4 days on/3 days off, 3 out of 4 weeks
Publikováno v:
Acta Neurochirurgica. 162:2837-2848
Sepsis is a systemic, inflammatory response to infection associated with significant morbidity and mortality. There is a considerable lack of literature exploring sepsis in neurosurgery. We aimed to identify variables that were correlated with mortal
Autor:
Luis Paz‐Ares, David R. Spigel, Yuanbin Chen, Maria Jove, Oscar Juan‐Vidal, Patricia Rich, Theresa Hayes, Vanesa Gutiérrez Calderón, Reyes Bernabe Caro, Alejandro Navarro, Afshin Dowlati, Bin Zhang, Yan Moore, Xiaopan Yao, Jaba Kokhreidze, Santiago Ponce, Paul A. Bunn
Publikováno v:
CANCER
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
RESILIENT (NCT03088813) is a phase 2/3 study assessing the safety, tolerability, and efficacy of liposomal irinotecan monotherapy in patients with small cell lung cancer and disease progression on/after first-line platinum-based therapy. Here, we pre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::680d158944be2a7768767d9b0fb91f2a
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=15599
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=15599
Autor:
Alberto S. Pappo, Makoto Tahara, Russell J. Schilder, Theodore W. Laetsch, Ray McDermott, Barrett H. Childs, Cornelis M. van Tilburg, Jyoti D. Patel, Shivaani Kummar, Catherine M. Albert, Olaf Witt, Shivani Nanda, Alexander Drilon, Anna F. Farago, Birgit Geoerger, Erin R. Rudzinski, Marc Ladanyi, Ramamoorthy Nagasubramanian, Steven G. DuBois, Stefan M. Pfister, Kristoffer Staal Rohrberg, Leo Mascarenhas, David M. Hyman, Jordan Berlin, Stefan S. Bielack, David S. Hong, Afshin Dowlati, François Doz, Noah Federman
Publikováno v:
The Lancet. Oncology, vol 21, iss 4
BackgroundThe selective TRK inhibitor larotrectinib was approved for paediatric and adult patients with advanced TRK fusion-positive solid tumours based on a primary analysis set of 55 patients. The aim of our analysis was to explore the efficacy and